Last reviewed · How we verify
Depiquick Birch (DPG103)
Depiquick Birch (DPG103) is a small molecule that targets the (unknown) mechanism.
Depiquick Birch (DPG103) is a small molecule that targets the (unknown) mechanism. Used for Phase 3 for (unknown).
At a glance
| Generic name | Depiquick Birch (DPG103) |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Further research is needed to understand the exact mechanism of action of Depiquick Birch (DPG103).
Approved indications
- Phase 3 for (unknown)
Common side effects
- Unknown
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |